Payment overview · 2025
General Payments
$717.58
31 reported records · 12 companies
Healthcare provider profile · identity verified
John M Peric, MD
Allopathic & Osteopathic Physicians|Family Medicine · BURBANK, CA · NPI 1285664664
Verified facts
What the public records show
CMS Open Payments records show John M Peric, MD received $717.58 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.36 | 28.5% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.41 | 13.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.02 | 11.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.94 | 7.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $50.05 | 7.0% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $40.84 | 5.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $39.95 | 5.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.18 | 5.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.59 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.76 | 4.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.03 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.45 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $717.58 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.08 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $97.41 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.02 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.28 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.94 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $39.95 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.59 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $29.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.76 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 71 |
| Methylprednisolone | Methylprednisolone | 261 | 201 |
| Eliquis | Apixaban | 246 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 58 |
| Alprazolam | Alprazolam | 240 | 37 |
| Metformin Hcl | Metformin Hcl | 236 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 52 |
| Gabapentin | Gabapentin | 191 | 41 |
| Losartan Potassium | Losartan Potassium | 172 | 51 |
| Azithromycin | Azithromycin | 166 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 140 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 24 |
| Trazodone Hcl | Trazodone Hcl | 124 | 38 |
| Furosemide | Furosemide | 119 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 20 |
| Lorazepam | Lorazepam | 88 | 15 |
| Lisinopril | Lisinopril | 83 | 24 |
| Diazepam | Diazepam | 81 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 19 |
| Omeprazole | Omeprazole | 79 | 25 |
| Montelukast Sodium | Montelukast Sodium | 78 | 23 |
| Potassium Chloride | Potassium Chloride | 77 | 21 |
| Sertraline Hcl | Sertraline Hcl | 73 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 17 |
| Tramadol Hcl | Tramadol Hcl | 67 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 48 |
| Simvastatin | Simvastatin | 59 | 15 |
| Carvedilol | Carvedilol | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 57 | 24 |
| Ozempic | Semaglutide | 57 | suppressed |
| Allopurinol | Allopurinol | 55 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Diclofenac Potassium | Diclofenac Potassium | 53 | 43 |
| Valsartan | Valsartan | 52 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 18 |
| Jardiance | Empagliflozin | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 33 |
| Finasteride | Finasteride | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 21 |
| Liothyronine Sodium | Liothyronine Sodium | 42 | suppressed |
| Baclofen | Baclofen | 41 | 17 |
| Famotidine | Famotidine | 41 | suppressed |
| Meloxicam | Meloxicam | 39 | 13 |
| Hydrocortisone | Hydrocortisone | 37 | 16 |
| Ondansetron Odt | Ondansetron | 37 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Glipizide | Glipizide | 33 | 14 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Ofloxacin | Ofloxacin | 27 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Levocarnitine | Levocarnitine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Hydroxyurea | Hydroxyurea | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 14 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Restasis | Cyclosporine | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $717.58 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, Dexcom G6 Transmitter, Grastek, JARDIANCE, LOREEV XR, OTEZLA, Odactra, QULIPTA, REPATHA, REXULTI, Ragwitek, Saxenda, TERIPARATIDE, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error